Shopping Cart
- Remove All
- Your shopping cart is currently empty
LY 178002 is an effective inhibitor of 5-lipoxygenase (5-LPO), phospholipase A2 (IC50: 0.6 μM for 5-lipoxygenase). LY 178002 also inhibits cellular production of LTB4 by human polymorphonuclear leukocytes and displays relatively weak inhibition on cyclooxygenase.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $1,520 | 6-8 weeks | |
50 mg | $1,980 | 6-8 weeks | |
100 mg | $2,500 | 6-8 weeks |
Description | LY 178002 is an effective inhibitor of 5-lipoxygenase (5-LPO), phospholipase A2 (IC50: 0.6 μM for 5-lipoxygenase). LY 178002 also inhibits cellular production of LTB4 by human polymorphonuclear leukocytes and displays relatively weak inhibition on cycloox |
Targets&IC50 | PLA2:6.3 μM, COX:, FCO:4.2 μM, 5-LPO:0.6 μM |
In vitro | LY178002 suppresses the generation of LTB4, PLA2 and FCO (IC50s of 0.1, 6.3 and 4.2 μM) . |
In vivo | LY 178002 (50 mg/kg) inhibits soft tissue swelling in the uninjected paw by 81% and prevents bone damage in rats. In the FCA model, LY 178002 (50 mg/kg; p.o.) inhibits uninjected paw swelling by 75%. The minimum effective dose for LY 178002 is 10 mg/kg (p.o.). |
Molecular Weight | 319.46 |
Formula | C18H25NO2S |
Cas No. | 107889-32-7 |
Relative Density. | 1.31g/cm3 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.